Stoking Functional Copies of Genes to Compensate for Mutated Ones

Ed Kaye, CEO of Stoke Therapeutics, discusses the company’s platform technology to address diseases in which people have one functional copy of a gene and one mutated copy, how it works, and its lead program in Dravet syndrome.